Severe Psoriasis Linked to Higher Risk of Earlier Death
Title: Severe Psoriasis Linked to Higher Risk of Earlier DeathCategory: Health NewsCreated: 9/5/2017 12:00:00 AMLast Editorial Review: 9/6/2017 12:00:00 AM
This article is protected by copyright. All rights reserved.
A study shows that not only is psoriasis independently tied to risk of type 2 diabetes, but that the risk rises with severity of the skin disease.
Summary BackgroundInfections are associated with biological therapies in psoriasis. ObjectivesTo summarize the incidence of infections in patients with moderate‐to‐severe psoriasis treated with ixekizumab, an anti‐interleukin‐17A monoclonal antibody. MethodsInfections are summarized from an integrated database of seven controlled and uncontrolled ixekizumab psoriasis trials. Data are presented from placebo‐controlled induction (weeks 0–12; UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3) and maintenance periods (weeks 12–60; UNCOVER‐1 and UNCOVER‐2), and all patients exposed to ixekizumab pooled from all...
ConclusionsNew‐onset anti‐TNF‐α‐induced eruptions previously classified as psoriasis or spongiotic dermatitis (eczema) exhibit a molecular profile that is different from either of these disorders.This article is protected by copyright. All rights reserved.
The FDA has given a regulatory green light to the first device that reduces opioid withdrawal symptoms. The NSS-2 Bridge from Innovative Health Solutions, a Versailles, Indiana firm, is stuck to the skin behind the ear and relies on four electrodes that are attached around the ear. The electrodes are used to deliver electric current to a set of occipital and cranial nerves (V, VII, IX, and X), hopefully helping addicts to avoid agitation, insomnia, and other symptoms of kicking opioids. The same device was approved by the FDA three years ago for use in acupuncture and the current approval went under the de novo review...
Accurate Diagnosis and Evidence-Based Comprehensive Care in Psoriasis: The Integral Role of Family Practice and General Practice Physicians
In this report, we demonstrated that in vitro, DZ2002 significantly decreased the expression of pro-inflammatory cytokines and adhesion molecule including IL-1α, IL-1β, IL-6, IL-8, TNF-α and ICAM-1 by inhibiting the phosphorylation of p38 MAPK, ERK and JNK in TNF-α/IFN-γ-stimulated HaCaT human keratinocytes. Topical administration of DZ2002 alleviated the imiquimod (IMQ)-induced psoriasis-like skin lesions and inflammation in mice, the therapeutic effect was comparable with the Calcipotriol. Moreover, the inflammatory skin disorder was restored by DZ2002 treatment characterized by reducing both...
ConclusionDespite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate‐to‐severe palmoplantar psoriasis.
ConclusionBiologic therapy is effective and well-tolerated for the treatment of hyperkeratotic PP, but less data are available on the treatment of pustular PP or PPP. Adalimumab, guselkumab, ixekizumab, secukinumab, and ustekinumab all showed > 80% efficacy for the treatment of hyperkeratotic PP, while infliximab and ustekinumab showed moderate efficacy for the treatment of pustular PP, and infliximab was the most efficacious treatment for PPP.
Conclusion: The results suggested a pathogenesis mechanism of psoriasis and indicated novel therapeutic targets for psoriasis.Dermatology